Breaking News Instant updates and real-time market news.

BAYRY

Bayer

$0.00

(0.00%)

, JNJ

Johnson & Johnson

$128.29

0.075 (0.06%)

08:57
09/03/19
09/03
08:57
09/03/19
08:57

Bayer hires Marianne De Backer as head of pharmaceuticals business development

Bayer (BAYRY) announced Marianne De Backer PhD as the new Head of Business Development & Licensing of its Pharmaceuticals Division. She will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of the company's Pharmaceuticals Division and join the Pharmaceuticals Executive Committee with immediate effect. De Backer will be based in Berkeley, CA, USA and lead Bayer's external pharmaceutical growth strategy and activities globally in all key areas of pharmaceutical innovation and alliance management. De Backer joins Bayer from Johnson & Johnson (JNJ) where she spearheaded Business Development activities across different therapeutic areas and geographies. She most recently held the position of Vice President of M&A Operations and Divestitures for the Pharmaceuticals Group and led Infectious Diseases & Vaccines Business Development including transactions, acquisitions, scientific licensing and alliance management.

BAYRY

Bayer

$0.00

(0.00%)

JNJ

Johnson & Johnson

$128.29

0.075 (0.06%)

  • 04

    Sep

  • 07

    Sep

  • 09

    Sep

  • 09

    Sep

  • 15

    Sep

  • 16

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 15

    Oct

BAYRY Bayer
$0.00

(0.00%)

06/04/19
PIPR
06/04/19
NO CHANGE
Target $32
PIPR
Overweight
Piper remains buyer of Arvinas after 'transformative' Bayer alliance
Piper Jaffray analyst Edward Tenthoff views Arvinas' (ARVN) alliance with Bayer (BAYRY) as "transformative." He's a buyer of the stock ahead of the Phase I ARV-110 data in metastatic castrate resistance prostate cancer in the second half of 2019. The analyst estimates Arvinas now holds pro forma cash of $225M to fund operations into the second half of 2021. Tenthoff reiterates an Overweight rating on Bayer with a $32 price target.
07/10/19
WBLR
07/10/19
NO CHANGE
WBLR
Market Perform
Elanco combination with Bayer unlikely for many reasons, says William Blair
Shares of Elanco Animal Health (ELAN) have been unusually volatility over the past two days, William Blair analyst John Kreger tells investors in a research note. On Monday, the FDA approved a generic version of the company's largest product, Rumensin, and yesterday, the media reported speculation that Bayer (BAYRY) has approached Elanco about combining their animal health businesses, the analyst explains. He believes that while a negative development, the Rumensin generic had been expected and thus does not change his modeling assumptions. The Bayer speculation is more surprising but does not seem likely to happen "for a number of reasons," says Kreger. Elanco's largest challenge is bolstering its organic revenue growth, and buying a large company that is growing at a slower pace would only add to this challenge, according the analyst. Further, Elanco has committed to deleverage its balance sheet in the coming year, he adds. And lastly, Kreger believes there could be antitrust challenges from such a large combination. He keeps a Market Perform rating on Elanco shares.
08/15/19
UBSW
08/15/19
UPGRADE
Target $30
UBSW
Neutral
Elanco upgraded to Neutral from Sell at UBS
UBS analyst Navin Jacob upgraded Elanco Animal Health (ELAN) to Neutral from Sell with a price target of $30, down from $31. While the analyst still see risks to the company's fundamentals from African swine fever and generic Rumensin, he believes the shares are more fairly valued at current levels. Further, some of these headwinds may be offset by companion animal strength, Jacob tells investors in a research note. While concerns of a potential deal with Bayer (BAYRY) have pushed Elanco shares lower, "forecastable" concerns are built in at current levels, says the analyst.
08/26/19
BOFA
08/26/19
DOWNGRADE
Target $30
BOFA
Neutral
BofA/Merrill downgrades Elanco to Neutral on Bayer deal uncertainty
BofA/Merrill analyst Michael Ryskin downgraded Elanco Animal Health (ELAN) to Neutral from Buy with a $30 price target. While the acquisition of Bayer's (BAYRY) Animal Health business could turn out positive in the longer term, there is too much uncertainty in the near-term, including which parts of the portfolio will be divested due to antitrust issues, Ryskin tells investors in a research note. The analyst does not expect answers until nearer to deal close, which is expected in mid-2020.
JNJ Johnson & Johnson
$128.29

0.075 (0.06%)

08/27/19
LEHM
08/27/19
NO CHANGE
Target $140
LEHM
Equal Weight
Barclays views J&J ruling as favorable, keeps Equal Weight rating
The $572M ruling last night against Johnson & Johnson is far less than the $17.2B Oklahoma was asking for and less than what the market was bracing for, Barclays analyst Kristen Stewart tells investors in a research note. As such, the analyst views the ruling favorably and believes it could ultimately be lower following J&J's appeal. However, litigation has and is likely to remain an overhang for the stock, says the analyst. She keeps an Equal Weight rating on shares of Johnson & Johnson with a $140 price target.
08/27/19
WELS
08/27/19
NO CHANGE
WELS
Outperform
Opioid ruling should assuage Johnson & Johnson investor fears, says Wells Fargo
Wells Fargo analyst Larry Biegelsen thinks decision in Oklahoma is a net positive for Johnson & Johnson in that the amount the judge ordered the company to pay - $572M - was well below the amount the plaintiffs requested - $17.5B. Further, the analyst notes that the amount was for abatement of the entire opioid crisis in Oklahoma, not just Johnson & Johnson's share of it, which seems like something the company should be able to overturn or reduce on appeal. Although J&J plans to appeal the ruling, Biegelsen expects the company to eventually settle this and other opioid cases. Big picture, he estimates Johnson & Johnson will eventually settle the opioid litigation for between $5B-10B payable over several years which admittedly is a rough guess at this time. He has an Outperform rating on the shares.
08/27/19
JPMS
08/27/19
NO CHANGE
JPMS
Neutral
Johnson & Johnson verdict well below feared worst case, says JPMorgan
The $572M verdict against Johnson & Johnson in Oklahoma came in well below the feared worst case, as investor expectations for the verdict increased over the past few weeks to over $1B, JPMorgan analyst Chris Schott tells investors in a research note. Further, the analyst believes the company has "strong legal grounding" to potentially overturn and/or reduce the verdict. Nonetheless, Schott still sees a more balanced risk/reward near-term for J&J shares and remain on the sidelines with a Neutral rating.
08/27/19
FBCO
08/27/19
NO CHANGE
Target $156
FBCO
Outperform
Opioid ruling reduces uncertainty, helps J&J move higher, says Credit Suisse
Credit Suisse analyst Matt Miksic notes that Johnson & Johnson appeared to react favorably to Oklahoma opioid ruling, due in part, to the $572M penalty being substantially lower than the $17B sought by State prosecutors. The analyst believes the decision helped reduce the range of uncertainty related to the potential opioid-related liability Johnson & Johnson could face, specifically in Oklahoma, if not across the U.S. more broadly. Miksic reiterates an Outperform rating and $156 target on the shares.

TODAY'S FREE FLY STORIES

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:35
09/22/19
09/22
19:35
09/22/19
19:35
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

BNPQY

BNP Paribas

$0.00

(0.00%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

TEVA

Teva

$7.44

-0.08 (-1.06%)

ENDP

Endo

$3.48

0.115 (3.42%)

MNK

Mallinckrodt

$2.46

0.01 (0.41%)

ABT

Abbott

$83.56

0.35 (0.42%)

AMRX

Amneal Pharmaceuticals

$3.34

0.21 (6.71%)

MYL

Mylan

$21.01

0.03 (0.14%)

MCK

McKesson

$146.83

1.06 (0.73%)

CAH

Cardinal Health

$47.89

-0.14 (-0.29%)

ABC

AmerisourceBergen

$85.13

0.475 (0.56%)

WAB

Wabtec

$74.01

0.26 (0.35%)

CVS

CVS Health

$64.28

0.65 (1.02%)

REAL

RealReal

$17.00

0.21 (1.25%)

CMG

Chipotle

$835.17

3.67 (0.44%)

MCD

McDonald's

$209.44

-1.12 (-0.53%)

YUM

Yum! Brands

$112.31

-1.83 (-1.60%)

WEN

Wendy's

$20.77

0.22 (1.07%)

QSR

Restaurant Brands

$72.64

-1.24 (-1.68%)

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

DAL

Delta Air Lines

$58.63

-0.05 (-0.09%)

FANG

Diamondback Energy

$96.90

-0.45 (-0.46%)

EHC

Encompass Health

$64.41

-0.01 (-0.02%)

FB

Facebook

$189.88

-0.27 (-0.14%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

PG

Procter & Gamble

$122.22

0.37 (0.30%)

KO

Coca-Cola

$53.90

-0.62 (-1.14%)

PEP

PepsiCo

$134.49

-0.98 (-0.72%)

CL

Colgate-Palmolive

$70.97

0.01 (0.01%)

KMB

Kimberly-Clark

$135.13

0.9 (0.67%)

K

Kellogg

$63.79

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 08

    Oct

  • 10

    Oct

  • 15

    Oct

  • 16

    Oct

  • 18

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 01

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

BGNE

BeiGene

$135.62

2.61 (1.96%)

19:34
09/22/19
09/22
19:34
09/22/19
19:34
Hot Stocks
BeiGene announces results on Tislelizumab from ongoing clinical trials »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 15

    Oct

  • 27

    Feb

CE

Celanese

$122.73

-1.06 (-0.86%)

19:24
09/22/19
09/22
19:24
09/22/19
19:24
Hot Stocks
Celanese experiences emergency incident at Clear Lake facility »

Celanese experienced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$379.33

-5.28 (-1.37%)

19:21
09/22/19
09/22
19:21
09/22/19
19:21
Periodicals
Indonesia to fault 737 Max design, oversight lapses in Lion Air crash, WSJ says »

Indonesian investigators…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AA

Alcoa

$21.70

-0.26 (-1.18%)

19:15
09/22/19
09/22
19:15
09/22/19
19:15
Downgrade
Alcoa rating change at Goldman Sachs »

Alcoa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

AA

Alcoa

$21.70

-0.26 (-1.18%)

, SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

19:15
09/22/19
09/22
19:15
09/22/19
19:15
Downgrade
Alcoa downgraded to Neutral from Buy at Goldman Sachs »

Goldman Sachs analyst…

AA

Alcoa

$21.70

-0.26 (-1.18%)

SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

19:08
09/22/19
09/22
19:08
09/22/19
19:08
Downgrade
Commercial Metals rating change at Goldman Sachs »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

19:06
09/22/19
09/22
19:06
09/22/19
19:06
Downgrade
Schnitzer Steel rating change at Goldman Sachs »

Schnitzer Steel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNSR

Finisar

$24.31

1.25 (5.42%)

18:15
09/22/19
09/22
18:15
09/22/19
18:15
Hot Stocks
Finisar presents new products, technologies at ECOC 2019 »

Finisar introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNPQY

BNP Paribas

$0.00

(0.00%)

, DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

18:04
09/22/19
09/22
18:04
09/22/19
18:04
Periodicals
Deutsche Bank nearing deal to transfer prime assets to BNP, Reuters says »

Deutsche Bank (DB) is…

BNPQY

BNP Paribas

$0.00

(0.00%)

DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSK

Verisk Analytics

$158.47

-0.21 (-0.13%)

18:00
09/22/19
09/22
18:00
09/22/19
18:00
Initiation
Verisk Analytics initiated at Keefe Bruyette »

Verisk Analytics assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.92

0.78 (2.10%)

, CMCSA

Comcast

$46.36

-0.32 (-0.69%)

16:58
09/22/19
09/22
16:58
09/22/19
16:58
On The Fly
Box Office Battle: 'Downton Abbey' wins weekend with $31M »

"Box Office Battle" is…

T

AT&T

$37.92

0.78 (2.10%)

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$59.19

-0.19 (-0.32%)

LGF.A

Lionsgate

$9.49

-0.47 (-4.72%)

LGF.B

Lionsgate

$8.88

-0.435 (-4.67%)

DIS

Disney

$132.18

-1.14 (-0.86%)

VIAB

Viacom

$24.92

-0.28 (-1.11%)

VIA

Viacom

$26.67

-0.85 (-3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

VIVHY

Vivendi

$0.00

(0.00%)

, MDSO

Medidata

$91.77

-0.04 (-0.04%)

16:01
09/22/19
09/22
16:01
09/22/19
16:01
Periodicals
Vivendi to widen legal battle against Mediaset beyond Italy, Reuters says »

Vivendi (VIVHY) is taking…

VIVHY

Vivendi

$0.00

(0.00%)

MDSO

Medidata

$91.77

-0.04 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

15:57
09/22/19
09/22
15:57
09/22/19
15:57
Periodicals
Some WeWork board members seeing to remove Neumann as CEO, WSJ says »

A bloc of WeWork…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

15:54
09/22/19
09/22
15:54
09/22/19
15:54
Periodicals
SoftBank turns against WeWork's parent CEO, Reuters reports »

SoftBank (SFTBY), the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$24.92

-0.28 (-1.11%)

, VIA

Viacom

$26.67

-0.85 (-3.09%)

15:48
09/22/19
09/22
15:48
09/22/19
15:48
Hot Stocks
Viacom acquires exclusive cable rights to Seinfeld from Sony Pictures Television »

Viacom (VIAB, VIA)…

VIAB

Viacom

$24.92

-0.28 (-1.11%)

VIA

Viacom

$26.67

-0.85 (-3.09%)

SNE

Sony

$59.19

-0.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

PWR

Quanta Services

$37.61

-0.28 (-0.74%)

12:22
09/22/19
09/22
12:22
09/22/19
12:22
Conference/Events
Quanta Services management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

PTEN

Patterson-UTI

$9.66

0.01 (0.10%)

12:21
09/22/19
09/22
12:21
09/22/19
12:21
Conference/Events
Patterson-UTI management to meet with Stephens »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ESE

Esco Technologies

$78.44

-1.54 (-1.93%)

12:19
09/22/19
09/22
12:19
09/22/19
12:19
Conference/Events
Esco Technologies management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

CSGP

CoStar Group

$595.10

-3.87 (-0.65%)

12:16
09/22/19
09/22
12:16
09/22/19
12:16
Conference/Events
CoStar Group participates in a conference call with Stephens »

Conference call with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 13

    Nov

CNNE

Cannae Holdings

$28.05

0.875 (3.22%)

12:02
09/22/19
09/22
12:02
09/22/19
12:02
Conference/Events
Cannae Holdings management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 13

    Nov

ANDE

Andersons

$26.28

-0.56 (-2.09%)

12:01
09/22/19
09/22
12:01
09/22/19
12:01
Conference/Events
Andersons management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

XGN

Exagen

$18.16

-0.425 (-2.29%)

, DDOG

Datadog

$36.20

-1.26 (-3.36%)

08:40
09/22/19
09/22
08:40
09/22/19
08:40
On The Fly
Opening Day: Datadog rises over 50% in market debut »

Shares of Datadog surged…

XGN

Exagen

$18.16

-0.425 (-2.29%)

DDOG

Datadog

$36.20

-1.26 (-3.36%)

PING

Ping Identity

$19.25

-0.8 (-3.99%)

IGMS

IGM Biosciences

$21.00

-0.7 (-3.23%)

NVST

Envista

$28.80

0.75 (2.67%)

PTON

Peloton

$0.00

(0.00%)

EDR

Endeavor

$0.00

(0.00%)

OPRT

Oportun Financial

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

CSCO

Cisco

$49.59

0.38 (0.77%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 13

    Nov

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

PG

Procter & Gamble

$122.22

0.37 (0.30%)

, KO

Coca-Cola

$53.90

-0.62 (-1.14%)

08:17
09/21/19
09/21
08:17
09/21/19
08:17
Periodicals
Kellogg, Coca-Cola among staples stocks for dividends, Barron's says »

Consumer-staples stocks…

PG

Procter & Gamble

$122.22

0.37 (0.30%)

KO

Coca-Cola

$53.90

-0.62 (-1.14%)

PEP

PepsiCo

$134.49

-0.98 (-0.72%)

CL

Colgate-Palmolive

$70.97

0.01 (0.01%)

KMB

Kimberly-Clark

$135.13

0.9 (0.67%)

K

Kellogg

$63.79

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 01

    Oct

  • 03

    Oct

  • 08

    Oct

  • 18

    Oct

  • 22

    Oct

  • 29

    Oct

  • 01

    Nov

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

, CMCSK

Comcast

$0.00

(0.00%)

08:09
09/21/19
09/21
08:09
09/21/19
08:09
Periodicals
Facebook, Microsoft among growth stocks for risky times, Barron's says »

Comcast (CMCSA), Delta…

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

DAL

Delta Air Lines

$58.63

-0.05 (-0.09%)

FANG

Diamondback Energy

$96.90

-0.45 (-0.46%)

EHC

Encompass Health

$64.41

-0.01 (-0.02%)

FB

Facebook

$189.88

-0.27 (-0.14%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 15

    Oct

  • 24

    Oct

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.